Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height

This trial evaluates whether long-term treatment with Genotropin normalizes final (adult) height in short children born small for gestational age

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Growth Disorder Growth Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participation in the 90-080 study

Exclusion criteria

Any severe, acute or chronic disease
Any other identifiable reason for short stature

Treatment and study plan

Treatment with Genotropin in different dosages

Drug

Primary outcomes

Final height, compared to the expected familial target height

Secondary outcomes

Body weight, body mass index at final height; adverse events and assessment of hematological and clinical chemistry

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium

Important dates

Study start: 2001
Study completion: 2005
First posted: Sep 15, 2005
Registry last updated: May 3, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed